Success and failure of artesunate treatment in five transplant recipients with disease caused by drug-resistant cytomegalovirus

Antiviral Research

Volumn 101, Issue 1, 2014, Pages 57-61

  Germi, R ^a,b   Mariette, C ^a   Alain, S ^c   Lupo, J ^a,b   Thiebaut, A ^a   Brion, J P ^a   Epaulard, O ^a,b   Saint Raymond, C ^a   Malvezzi, P ^a   Morand, P ^a,b  

^a GRENOBLE UNIVERSITY HOSPITAL   (France)

^b EUROPEAN MOLECULAR BIOLOGY LABORATORY   (France)

^c LIMOGES UNIVERSITY HOSPITAL   (France)

Author keywords

Artesunate; Cytomegalovirus; Multidrug resistance; Transplantation

Indexed keywords

ARTESUNATE; CIDOFOVIR; FOSCARNET; GANCICLOVIR; VALACICLOVIR; VALGANCICLOVIR; VIRUS DNA; ANTIVIRUS AGENT; ARTEMISININ DERIVATIVE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; ASYMPTOMATIC INFECTION; CLINICAL ARTICLE; CYTOMEGALOVIRUS INFECTION; CYTOPENIA; DEATH; DRUG DOSE INCREASE; DRUG RESISTANT CYTOMEGALOVIRUS; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; FEVER; GENE MUTATION; GENOTYPE; GRAFT RECIPIENT; GUILLAIN BARRE SYNDROME; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HERPES SIMPLEX; HODGKIN DISEASE; HUMAN; HUMAN CYTOMEGALOVIRUS; INFECTION PREVENTION; KIDNEY DYSFUNCTION; KIDNEY GRAFT; LUNG LAVAGE; MALE; MULTIDRUG RESISTANCE; NAUSEA AND VOMITING; NEUTROPENIA; ORGAN TRANSPLANTATION; PHENOTYPE; PRIMARY INFECTION; PRIORITY JOURNAL; RESPIRATORY FAILURE; TREATMENT RESPONSE; VIRAL RESPIRATORY TRACT INFECTION; VIRUS CHARACTERIZATION; VIRUS LOAD; VIRUS MUTATION; VIRUS PNEUMONIA; VIRUS REACTIVATION; WEGENER GRANULOMATOSIS; CYTOMEGALOVIRUS; HEMATOPOIETIC STEM CELL; MIDDLE AGED; NONHUMAN; PNEUMONIA; SEVERE RENAL IMPAIRMENT; CASE REPORT; DRUG EFFECT; GENETICS; ISOLATION AND PURIFICATION; TRANSPLANTATION; TREATMENT OUTCOME; VIROLOGY;

ARTESUNATE; CYTOMEGALOVIRUS;

ARTESUNATE; CYTOMEGALOVIRUS; MULTIDRUG RESISTANCE; TRANSPLANTATION;

ANTIVIRAL AGENTS; ARTEMISININS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DRUG RESISTANCE, VIRAL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; ORGAN TRANSPLANTATION; TRANSPLANTATION; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84888242344     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2013.10.014     Document Type: Article

References (22)

1. S. Alain, S. Hantz, C. Scieux, A. Karras, M.C. Mazeron, J.C. Szelag, B.M. Imbert, A.M. Fillet, S. Gouarin, C. Mengelle, A. De Wilde, N. Cogne, G. Champier, S. Rogez, C. Legendre, and F. Denis Detection of ganciclovir resistance after valaciclovir-prophylaxis in renal transplant recipients with active cytomegalovirus infection J. Med. Virol. 73 4 2004 566 573 (Pubitemid 38857207)
2. M. Boeckh, and P. Ljungman How we treat cytomegalovirus in hematopoietic cell transplant recipients Blood 113 23 2009 5711 5719
3. S. Chou, N.S. Lurain, K.D. Thompson, R.C. Miner, and W.L. Drew Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus J. Infect. Dis. 188 1 2003 32 39 (Pubitemid 36829739)
4. S. Chou, G.I. Marousek, L.C. Van Wechel, S. Li, and A. Weinberg Growth and drug resistance phenotypes resulting from cytomegalovirus DNA polymerase region III mutations observed in clinical specimens Antimicrob. Agents Chemother. 51 11 2007 4160 4162 (Pubitemid 350057819)
5. S. Chou Cytomegalovirus UL97 mutations in the era of ganciclovir and maribavir Rev. Med. Virol. 18 4 2008 233 246 (Pubitemid 352018847)
6. S. Chou, G. Marousek, S. Auerochs, T. Stamminger, J. Milbradt, and M. Marschall The unique antiviral activity of artesunate is broadly effective against human cytomegaloviruses including therapy-resistant mutants Antiviral Res. 92 2 2011 364 368
7. S. Cotin, C.A. Calliste, M.C. Mazeron, S. Hantz, J.L. Duroux, W.D. Rawlinson, M.C. Ploy, and S. Alain Eight flavonoids and their potential as inhibitors of human cytomegalovirus replication Antiviral Res. 96 2 2012 181 186
8. S. Gantt, M.L. Huang, A. Magaret, L. Bunts, S. Selke, A. Wald, P.J. Rosenthal, G. Dorsey, and C. Casper An artesunate-containing antimalarial treatment regimen did not suppress cytomegalovirus viremia J. Clin. Virol. 58 1 2013 276 278
9. E. Gault, Y. Michel, A. Dehée, C. Belabani, J.C. Nicolas, and A. Garbarg-Chenon Quantification of human cytomegalovirus DNA by real-time PCR J. Clin. Microbiol. 39 2 2001 772 775 (Pubitemid 32150860)
10. S. Hantz, F. Garnier-Geoffroy, M.C. Mazeron, I. Garrigue, P. Merville, C. Mengelle, L. Rostaing, F. Saint Marcoux, M. Essig, J.P. Rerolle, S. Cotin, R. Germi, S. Pillet, Y. Lebranchu, P. Turlure, S. Alain French CMV Resistance Survey Study Group Drug-resistant cytomegalovirus in transplant recipient: a French cohort study J. Antimicrob. Chemother. 65 12 2010 2628 2640
11. G. Härter, and D. Michel Antiviral treatment of cytomegalovirus infection: an update Expert. Opin. Pharmacother. 13 5 2012 623 627
12. R. He, K. Park, H. Cai, A. Kapoor, M. Forman, B. Mott, G.H. Posner, and R. Arav-Boger Artemisinin-derived dimer diphenyl phosphate is an irreversible inhibitor of human cytomegalovirus replication Antimicrob. Agents Chemother. 56 7 2012 3508 3515
13. R. He, M. Forman, B.T. Mott, R. Venkatadri, G.H. Posner, and R. Arav-Boger The unique and highly-selective anti-cytomegalovirus activities of artemisinin-derived dimer diphenyl phosphate stem from combination of dimer unit and a diphenyl phosphate moiety Antimicrob. Agents Chemother. 57 9 2013 4208 4214
14. C.N. Kotton, D. Kumar, A.M. Caliendo, A. Asberg, S. Chou, D.R. Snydman, U. Allen, A. Humar Transplantation Society International CMV Consensus Group International consensus guidelines on the management of cytomegalovirus in solid organ transplantation Transplantation 89 7 2010 779 795
15. P.K. Lau, M.L. Woods, S.K. Ratanjee, and G.T. John Atesunate is ineffective in controlling valganciclovir-resistant cytomegalovirus infection Clin. Infect. Dis. 52 2 2011 279
16. N.S. Lurain, and S. Chou Antiviral drug resistance of human cytomegalovirus Clin. Microbiol. Rev. 23 4 2010 689 712
17. G.M. Scott, A. Weinberg, W.D. Rawlinson, and S. Chou Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates Antimicrob. Agents Chemother. 51 1 2007 89 94 (Pubitemid 46047692)
18. M.Y. Shapira, I.B. Resnick, S. Chou, A.U. Neumann, N.S. Lurain, T. Stamminger, O. Caplan, N. Saleh, T. Efferth, M. Marschall, and D.G. Wolf Artesunate as a potent antiviral agent in a patient with late drug-resistant cytomegalovirus infection after hematopoietic stem cell transplantation Clin. Infect. Dis. 46 9 2008 1455 1457 (Pubitemid 351589951)
19. N. Schnepf, J. Corvo, M.J. Pors, and M.C. Mazeron Antiviral activity of ganciclovir and artesunate towards human cytomegalovirus in astrocytoma cells Antiviral Res. 89 2 2011 186 188
20. K.L. Springer, S. Chou, S. Li, R.H. Giller, R. Quinones, J.E. Shira, and A. Weinberg How evolution of mutations conferring drug resistance affects viral dynamics and clinical outcomes of cytomegalovirus-infected hematopoietic cell transplant recipients J. Clin. Microbiol. 43 1 2005 208 213 (Pubitemid 40096302)
21. D.G. Wolf, A. Shimoni, I.B. Resnick, T. Stamminger, A.U. Neumann, S. Chou, T. Efferth, O. Caplan, J. Rose, A. Nagler, and M. Marschall Human cytomegalovirus kinetics following institution of artesunate after hematopoietic stem cell transplantation Antiviral Res. 90 3 2011 183 186
22. K.C. Zhao, and Z.Y. Song Distribution and excretion of artesunate in rats Proc. Chin. Acad. Med. Sci. Peking Union. Med. Coll. 4 4 1989 186 188